Silverback Therapeutics will raise $241.5 million as the Seattle biotech company goes public Friday. Silverback priced its IPO on Thursday evening at $21 per share, which exceeded the high end… Read More
Silverback Therapeutics plans to raise up to $151.8 million in its initial public offering, the Seattle-based company said Monday in an updated IPO filing. The biotech firm will aim to… Read More
Seattle biotech startup Silverback Therapeutics raised a $78.5 million investment round to support development of its therapies for cancer, fibrosis, and other conditions. Founded in 2016, Silverback’s ImmunoTAC technology can… Read More